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A B S T R A C T
Purpose
Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular
endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated
clinical activity in patients with medullary thyroid cancer (MTC) in phase I.
Patients and Methods
We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients
with documented radiographic progression of metastatic MTC. Patients were randomly assigned
(2:1) to cabozantinib (140 mg per day) or placebo. The primary end point was progression-free
survival (PFS). Additional outcome measures included tumor response rate, overall survival,
and safety.
Results
The estimated median PFS was 11.2 months for cabozantinib versus 4.0 months for placebo
(hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P  .001). Prolonged PFS with cabozantinib was
observed across all subgroups including by age, prior TKI treatment, and RET mutation status
(hereditary or sporadic). Response rate was 28% for cabozantinib and 0% for placebo; responses
were seen regardless of RET mutation status. Kaplan-Meier estimates of patients alive and
progression-free at 1 year are 47.3% for cabozantinib and 7.2% for placebo. Common cabozantinib-
associated adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased weight
and appetite, nausea, and fatigue and resulted in dose reductions in 79% and holds in 65% of patients.
Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of
placebo-treated patients.
Conclusion
Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients
with progressive metastatic MTC and represents an important new treatment option for patients
with this rare disease. This dose of cabozantinib was associated with significant but
manageable toxicity.
J Clin Oncol 31:3639-3646. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Medullary thyroid cancer (MTC) is a rare malig-
nancy originating from calcitonin-producing para-
follicular C cells of the thyroid.1,2 The majority
(approximately 75%) of cases occur sporadically,
and the remaining arise as part of three inherited
autosomal dominant syndromes: multiple endo-
crine neoplasia 2A (MEN2A), MEN2B, or familial
MTC.3,4 Germline mutations in the gene encoding
the tyrosine kinase receptor rearranged during
transfection (RET) are present in almost all patients
with inherited MTC,5 and somatic mutations are
found in approximately 65% of patients with spo-
radic MTC.6-8 The activating point mutation
M918T, representingapproximately80%ofsomatic
RET mutations7 and 95% of MEN2B cases,9 is an
indicator for poor prognosis.7,10 In addition toRET,
the hepatocyte growth factor receptor (MET) and
vascular endothelial growth factor receptor 2
(VEGFR2) signaling pathways are upregulated in
thyroid tumors11,12 and have been implicated in the
pathogenesis ofMTC through promotion of proin-
vasive and proangiogenic phenotypes.13-15
Whereas complete surgical resection is curative
for some patients with MTC, patients with distant
metastases have a short median survival time, al-
though progression rates are variable.16 Serum
levels of calcitonin and carcinoembryonic antigen
(CEA) are important indicators of tumor burden
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and prognosis.17-22 Cytotoxic chemotherapy or radiotherapy have
limited, transient activity in patients with unresectable or metastatic
MTC.23 Although the tyrosine kinase inhibitor (TKI) vandetanib has
been approved for use in patients with locally advanced or metastatic
MTC, it has not been extensively examined in patients with docu-
mented radiographic disease progression at baseline.24
Cabozantinib is a TKI that targets three relevant pathways in
MTC: MET, VEGFR2, and RET.25 In a phase I study, cabozantinib
demonstrated promising clinical activity in a cohort of heavily pre-
treated patients withMTC.26We report here the results of an interna-
tional, double-blind, randomized, placebo-controlled phase III study
evaluating cabozantinib in patients with metastatic MTC and docu-
mented radiographic disease progression at study entry.27,28
PATIENTS AND METHODS
Eligibility Requirements
Eligible patients were adults with histologically confirmed, unresectable,
locally advanced, or metastatic MTC. Patients were required to have radio-
graphic disease progression per modified Response Evaluation Criteria in
Solid Tumors (mRECIST) guidelines29 at screening compared with an image
obtained within the prior 14 months. Documentation of progressive disease
(PD) to establish eligibility was by independent review in 89.4% of patients,
and by investigator assessment in the remaining patients. Exclusion criteria
included prior systemic anticancer therapy within 4 weeks or significant car-
diac, hematopoietic, hepatic, or renal dysfunction.Therewasno limit onprior
therapy, including exposure to other TKIs. All patients provided written in-
formed consent. The protocol was approved by ethics committees or institu-
tional review boards at each clinical site, nationally, or both.
Randomization and Treatments
Patients were randomly assigned in a 2:1 ratio to receive cabozantinib or
placebo in a double-blinded fashion and were stratified by age ( 65 years,
 65 years) and prior TKI treatment (yes, no). Patients received 140 mg
(freebase equivalent) of cabozantinib or placebo capsules orally once per day
until either intolerable toxicity or disease progression permRECISToccurred.
Dose holds and up to two dose-level reductions (to aminimumdose of 60mg
per day) were allowed. The study remained blinded until the primary analysis
of progression-free survival (PFS) and the interim analysis of overall survival
(OS) were complete. Patients receiving placebo were not permitted to cross
over to cabozantinib.
Efficacy
The primary end point was duration of PFS. Key secondary end points
included OS and objective response rate (ORR). The database cutoff date for
all planned analyses was June 15, 2011, except for the primary PFS analysis,
which was April 6, 2011 (when the 138th and 139th independent radiology
review committee [IRC] -determined PFS events occurred). Radiographic
tumor assessments were performed every 12 weeks ( 5 days) from random
assignmentuntil PD,usingmRECIST.Tumorassessmentswereperformedby
a blinded IRC to determine response and/or progression for the primary
efficacy analyses. PFS was calculated as the time from random assignment to
the earlier of documented PD per mRECIST or death.
Biomarker Measurements
Methods for determining RET mutational status and changes in calci-
tonin and CEA are provided in the Data Supplement. Tumor and blood
samples collectedat screeningwere analyzed forRETmutation; for a sample to
be considerednegative forRETmutation, the complete sequence for exons 10,
11, and 13 to 16must have been obtained and been free of mutation.30
Safety
Safety assessments includedmonitoring adverse events (AEs), perform-
ing standard laboratory tests (hematology, serum chemistry, and urinalysis)
and physical examinations, and recording ECGs. Severity of AEs was assessed
by using the National Cancer Institute’s Common Terminology Criteria for
Adverse Events, version 3.0. Serious AEs (SAEs) were defined in accordance
with the International Conference on Harmonisation Guidelines for Clinical
SafetyDataManagement:Definitions andStandards forExpeditedReporting,
Topic E2A.
Statistical Analysis
Efficacy analyses for PFS andOSused theKaplan-Meiermethod and the
stratified log-rank test for inference testing. The stratified Cox proportional
hazardsmodelwas used to estimate hazard ratios (HRs). The primary analysis
of PFSwas event driven, included radiographic progression events per the IRC
and deaths, and included all randomly assigned patients (ie, the intention-to-
treat population). Patients who received subsequent anticancer treatment
were censored. Prespecified subgroup analyses and planned sensitivity analy-
ses of PFS are described in the Data Supplement. Safety analyses included
patientswho receivedat least onedoseof study treatment. For theprimary end
point of PFS, the study was designed to have 90% power to detect an HR of
0.571 using the log-rank test and a two-sided significance level of 5%. This
corresponds to a 43% reduction in the risk of progression or death or a 75%
improvement inmedianPFS from8months to 14months. In all, 138progres-
sion events were required, and 315 patients were planned for enrollment. As a
result, all patients except the first 138 to experience an event were censored in
the PFS analysis, contributing time-to-event data until the date of censoring.
Statistical considerations for the end point of OS are described in the Data
Supplement. Statistical analysis was performed independently by the sponsor.
RESULTS
Patients
FromSeptember 2008 throughFebruary 2011, 330patients from
23 countries were randomly assigned 2:1 to receive cabozantinib (219
patients)orplacebo(111patients;Fig1).Baselinecharacteristics in the
treatment groups were well balanced (Table 1). Forty percent of
patients (n 133) had received prior anticancer therapy, and 21%
(n 68) received prior TKI treatment. Twenty-five percent had two
or more systemic therapies (24% cabozantinb; 28% placebo). Most
patients (285 [86%]) had sporadic disease. Approximately half the
patients (48.2%;n159)wereRETmutation–positive, 12%(n41)
wereRETmutation–negative, and 39% (n 130) had unknownRET
mutation status due to missing sequence data or to the presence of
a mutation of unknown significance. M918T was the predominant
RET mutation (74%; 118 of 159 patients with documented muta-
tions). The main sites of disease in the majority of patients included
lymph nodes, liver, lung, and bone.
Treatment
At the database cutoff date, 45% (98 of 219) of patients in the
cabozantinib arm and 14% (15 of 111) of patients in the placebo arm
were receiving study treatment. The arithmetic median duration of
exposurewas204days for cabozantinib-treatedpatients (interquartile
range, 99 to 392 days), almost twice that of placebo-treated patients
(median 105 days; interquartile range, 83 to 170 days). Because of the
large percentage of patients receiving treatment at data cutoff, the
median duration of exposure is an underestimate in the cabozantinib
treatment group. The median time of follow-up was 13.9 months
(range, 3.6 to 32.5 months).
PFS
The studymet its primary end point of demonstrating improve-
ment in PFS as determined by the IRC (Fig 2A). Cabozantinib treat-
ment led toa substantial improvement inPFScomparedwithplacebo.
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Estimatedmedian PFS durationwas 11.2months in the cabozantinib
group and 4.0 months in the placebo group. The stratified HR was
0.28 (95% CI, 0.19 to 0.40; P  .001). A tabulation of censoring
reasons is provided in the Data Supplement. Similar results were
obtained in analyses of PFS as determined by investigator (13.8- v
3.1-month median PFS; HR, 0.29; 95% CI, 0.21 to 0.42; P  .001).
HRs obtained in all planned sensitivity analyses of the primary end
point were similar to the primary analysis and varied within a narrow
range (0.28 to0.32;DataSupplement).TheKaplan-Meier estimatesof
the proportions of patients alive and progression-free at 1 year are
47.3% for the cabozantinib arm and 7.2% for the placebo arm.
Allprespecifiedpatient subgroupsdemonstratedprolongationof
PFS with cabozantinib treatment (HR 1), including those with or
without prior TKI treatment, bone metastases at baseline, and with
hereditary or sporadic forms ofMTC (Fig 2B andData Supplement).
All RET mutation subgroups showed improved PFS from treatment
(RET mutation [somatic or germline] status: positive, HR, 0.24; neg-
ative, HR, 0.47; unknown, HR, 0.30), although the CI for the RET
mutation–negative subgroup crosses 1.0.
Key Secondary Efficacy End Points
In total, 312 patients (95%) could be evaluated for tumor re-
sponse per IRC on the basis of measurable disease at baseline. The
ORR (IRC determined) was 28% in the cabozantinib arm (all partial
responses) and 0% in the placebo arm (P .001). The median esti-
mated duration of response was 14.6 months (95% CI, 11.1 to 17.5
months). RET mutation–positive and -negative subgroups also
demonstrated similar ORRs for cabozantinib treatment (32%
and 25%, respectively). Ninety-four percent (170 of 180) of
cabozantinib-treated patients with measurable disease at baseline
and at least one postbaseline assessment had a detectable decrease
in target lesion size compared with 27% (24 of 89) of placebo-
treated patients (Data Supplement).
A planned interim analysis of OS was conducted, including 96
(44%) of the 217 patient deaths required for the final analysis. In this
analysis, no statistically significant difference between treatment arms
was observed (HR, 0.98; 95% CI, 0.63 to 1.52). Survival follow-up is
planned to continue until at least 217 deaths have been observed.
Calcitonin and CEA
Calcitonin and CEA response at week 12 was evaluable in 140
(64%)and170(78%)cabozantinib-treatedpatientsand61(55%)and
71 (64%) placebo-treated patients, respectively. The most common
reasons patients were not evaluable were the lack of a week-12 assess-
ment or a calcitonin assay change between the baseline and week-12
assessments (details are provided in the Data Supplement). At base-
line, themean value and standard deviation (SD) for calcitonin in the
cabozantinib and placebo arms were 6,370 pmol/L (SD, 11,332
pmol/L) and8,846pmol/L (SD,15,722pmol/L), respectively (Welsh’s
t testP .27). ForCEA, themeanvalues for cabozantinib andplacebo
arms were 736 g/L (SD, 3,555 g/L) and 1,108 g/L (SD, 5,168
g/L), respectively (Welsh’s t testP .58). These baseline valueswere
judged tobenotmeaningfully different. Frombaseline toweek 12, the
cabozantinib arm displayed significant decreases in calcitonin (mean,
45.2% [SD, 60.71%]) compared with increases in the placebo arm
(57.3%;SD,115.4%;P .001).Changes inCEAlevels frombaseline
to week 12 showed a similar trend (23.7% [SD, 58.21%] in the
cabozantinib arm v 88.7% [SD, 182.%] in the placebo arm;
P .001.Agenerally linear relationshipwasobservedwhenchanges in
calcitonin and CEA from baseline to week 12 (up to approximately
200% increases) were compared with changes in target lesion size
(Fig 3).
Safety and Tolerability
AEs reported in  10% of cabozantinib-treated patients are
summarized inTable2.Grade3or4AEswere reported in69%(148of
214) and 33% (36 of 109) of patients in the cabozantinib and placebo
groups, respectively. In cabozantinib-treated patients, the most fre-
quently reported grade 3 or 4 AEs were diarrhea (15.9%), palmar-
plantar erythrodysesthesia (12.6%), and fatigue (9.3%). AEs typically
Not randomly assigned
   Did not meet eligibility criteria
   Voluntary discontinuation
(n = 218)
 (n = 214)
(n = 4)
Assigned to placebo arm (n = 111)Assigned to cabozantinib arm (n = 219)
Included in ITT population
Included in safety population
(n = 111)
(n = 109}
Included in ITT population
Included in safety population
(n = 219)
(n = 214)
Continued treatment
Discontinued treatment
   Did not receive treatment
   PD
   AE
   Death
   Participant request
   Investigator decision
   Other
45%
55%
2%
26%
16%
5%
4%
1%
1%
Continued treatment
Discontinued treatment
  Did not receive treatment
   PD
   AE
   Death
   Participant request
   Investigator decision
   Other
14%
86%
2%
60%
8%
5%
12%
0%
0%
Assessed for eligibility
(N = 548)
Randomly assigned (2:1)
(n = 330) Fig 1. Random assignment and out-
comes. Patient disposition as of June 15,
2011. High screen fail rate was largely
because of a lack of confirmation of pro-
gressive disease (PD) by the independent
radiology review committee. AE, adverse
event; ITT, intention-to-treat.
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associated with vascular endothelial growth factor (VEGF) path-
way inhibition,24,26,31-33 including hypertension, hemorrhage, fistula
formation, and GI perforation, occurred more frequently among
cabozantinib-treated patients (Table 3).
Laboratoryabnormalitieswithahigher incidence in thecabozan-
tinib arm (between arm difference of 5% all grades or 2% grade
3 to 4) consisted of increased AST, increased ALT, increased alkaline
phosphatase, hypocalcemia, hypophosphatemia, hyperbilirubinemia,
hypomagnesemia, hypokalemia, hyponatremia, lymphopenia, neu-
tropenia, and thrombocytopenia (Data Supplement). There was no
drug-induced severe liver injury. Thyroid-stimulating hormone
(TSH) level above normalwas noted after treatment initiation in 57%
of cabozantinib patients compared with 19% of placebo patients.
AEs were generally managed with concomitant medications,
dose interruptions, and dose reductions; 79% (169 of 214) of
cabozantinib-treated patients and 9% (10 of 109) of placebo patients
had dose reductions. Sixty-five percent (140 of 214) of cabozantinib-
treated patients and 17% (19 of 109) of placebo patients had dose
interruptions due to AEs. AEs were listed as the primary reason for
treatment discontinuation in 16%(35of 214) of cabozantinib-treated
patients and in 8% (nine of 109) of placebo-treated patients. In addi-
tion, 6% (12 of 214) of the patients in the cabozantinib arm discon-
tinued treatment for reasons other than PD, AE, or death; 11 of these
patients had ongoing AEs at the time of treatment discontinuation,
although AEs were not reported as the primary reason for treatment
discontinuation in these patients.
SAEs were more frequent in cabozantinib- versus placebo-
treated patients (42.1% [90 of 214] v 22.9% [25 of 109]). SAEs that
occurredat a2%frequency in cabozantinib- versusplacebo-treated
patients includedmucosal inflammation(2.8%[sixof214]v0%[zero
of 109]), hypocalcemia (2.8%[six of 214] v 0%[zero of 109]), pulmo-
nary embolism (2.3% [five of 214] v 0% [zero of 109]), and hyperten-
sion (2.3% [five of 214] v 0% [zero of 109]). At the planned interim
analysis theoverall death ratewasbalancedbetween the two treatment
arms. Ninety-six deaths were reported: 65 (30%) in the cabozantinib
groupand30(28%) in theplacebogroup,andonepatientwhodidnot
receive studydrug.Most deathswere attributed todisease progression
(77% [50 of 65] in the cabozantinib arm and 80% [24 of 30] in the
placebo arm).
Grade 5 AEs occurring within 30 days of last dose were reported
in 7.9% of cabozantinib-treated patients and 7.3% of placebo-treated
patients. Grade 5 AEs on the cabozantinib arm consisted of fistula
(three patients, including one patientwith concurrent pneumonia, all
related), respiratory failure (two patients, one related), hemorrhage
(two patients, one related), multiorgan failure (two patients, none
related), and sepsis (not related), sepsis/multiorgan failure (related),
suddendeath (related),hepatic failure (not related), cardiopulmonary
failure (related), pneumonia (not related), general physical health
deterioration(not related), anddeathnototherwise specified(related)
in one patient each. Grade 5 AEs on the placebo arm consisted of
dysphagia (not related), cardiopulmonary failure (deemed related),
shock (likely septic shock, not related), acute respiratory distress syn-
drome (not related), pneumonia (not related), pneumonia/general
physical health deterioration (deemed related), hepatic failure (not
related), and asthenia (not related) in one patient each. Some of the
grade 5 AEs in both treatment arms were reported in patients whose
primary cause of death was reported as PD.
DISCUSSION
PatientswithprogressiveMTChave limited treatment options.Cabo-
zantinib was associated with an improvement in estimated PFS com-
pared with placebo in a patient population with documented
Table 1. Baseline Demographic and Disease Characteristics
Characteristic
Cabozantinib
(n  219)
Placebo
(n  111)
No. % No. %
Male sex 151 68.9 70 63.1
Age, years
Median 55.0 55.0
Range 20-86 21-79
 65 172 78.5 86 77.5
 65 47 21.5 25 22.5
ECOG PS
0 123 56.2 56 50.5
1-2 95 43.4 55 49.5
RET mutation status
Positive 101 46.1 58 52.3
Negative 31 14.2 10 9.0
Unknown 87 39.7 43 38.7
MTC disease type
Hereditary 12 5.5 8 7.2
Sporadic 191 87.2 94 84.7
Unknown 16 7.3 9 8.1
RET M918T mutation status
Positive 75 34.2 43 38.7
Negative 67 30.6 30 27.0
Unknown 77 35.2 38 34.2
Patients with prior anticancer therapy 85 38.8 48 43.2
Patients with prior systemic therapy for MTC 81 37.0 47 42.3
Patients with two or more prior systemic
therapies 52 23.7 31 27.9
Patients with prior thyroidectomy 201 91.8 104 93.7
Prior TKI status
Yes† 44 20.1 24 21.6
Vandetanib 25 11.4 9 8.1
Sorafenib 11 5.0 8 7.2
Motesanib 7 3.2 2 1.8
Sunitinib 6 2.7 3 2.7
No 171 78.1 86 77.5
Unknown 4 1.8 1 0.9
No. of organs and anatomic locations
involved at enrollment
0-1 28 12.8 15 13.5
 2 191 87.2 96 86.5
Main sites of metastatic disease
Lymph nodes 175 79.9 86 77.5
Liver 152 69.4 67 60.4
Lung 116 53.0 64 57.7
Bone 112 51.1 56 50.5
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance
status; MTC, medullary thyroid cancer; RET, rearranged during transfection;
TKI, tyrosine kinase inhibitor.
In the M918T unknown category, five of 77 patients in the cabozantinib
group and four of 38 in the placebo group exhibited mutations in other exons
and are therefore less likely to harbor an M918T mutation.
†Other prior TKI treatments not shown in the table: axitinib (three patients),
pazopanib (three patients), and imatinib (two patients).
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progressive MTC, with an increase of more than 7 months in esti-
matedmedianPFScomparedwithplacebo, anda confirmed response
rate of 28%. Importantly, benefit from the use of cabozantinib was
observed acrossmultiple sensitivity and subgroup analyses, including
priorTKI or systemic therapy, the presence of bonemetastases, and in
all RET mutation subgroups analyzed.
This study is one of the largest conducted in patients withMTC.
Tothebestofourknowledge, it is thefirst randomizedphase III trial in
a population of patients with MTC rigorously defined with PD per
mRECISTwithin adefined timeperiod (14months) required at study
entry. This population with advanced disease had a short estimated
median PFS of 4.0 months and a high rate of morbidity reported as
AEs in the placebo arm. The poor prognosis of patients enrolled onto
the cabozantinib study is in contrast to the patient population studied
in the vandetanib phase III trial, in which PD per mRECIST was not
requiredat studyentry, and forwhich theestimatedmedianPFS in the
placebo arm was 19.3 months.24 This suggests that the patient popu-
lation studied in the vandetanib trial had relatively indolent disease
B
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Fig 2. (A) Kaplan-Meier estimates of
progression-free survival (PFS) in the
intention-to-treat population on the basis
of central assessment of radiographic im-
ages with analyses stratified according
to age and prior tyrosine kinase inhibitor
treatment. The estimated median PFS
was 7.2 months longer in the cabozantinib
group than in the placebo group. (B) Un-
stratified hazard ratios (HRs) and 95% CIs
for subgroup analyses of estimated PFS
by prespecified baseline characteristics
and by ad hoc RET mutational characteris-
tics (sporadic, hereditary, and M918T status).
The HRs for the categories of unknown prior
tyrosine kinase inhibitor treatment and bone-
only metastases at baseline were not quanti-
fiable because of the small numbers of
patients in these subgroups. (*) Prior antican-
cer regimens include local and systemic
therapy. ECOG PS, Eastern Cooperative On-
cology Group performance status; IRC, inde-
pendent radiology review committee.
Cabozantinib in Progressive Medullary Thyroid Cancer
www.jco.org © 2013 by American Society of Clinical Oncology 3643
Downloaded from ascopubs.org by 131.114.244.42 on March 29, 2019 from 131.114.244.042
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
and confirms that patients who were enrolled onto the cabozantinib
study were in significant need of therapy.
At the planned interim analysis forOS, no statistically significant
difference between treatment armswas observed. The final analysis of
survival will be conducted after 217 events have occurred. This study
could offer a unique opportunity to explore a relationship between
PFS and OS inMTC.
Recent research has suggested that RET inhibition can lead to
early changes in calcitonin levels independent of changes in tumor
size,34 but in this study, correlationswereobservedbetweenchanges in
both calcitonin and CEA from baseline to week 12 and changes in
target lesion size, suggesting that these serummarkersmay be predic-
tive of patient benefit.
The most frequent grade 3 or 4 AEs were diarrhea, palmar-
plantar erythrodysesthesia, and fatigue, generally consistent with
those seen in studies with VEGF pathway inhibitors, with other TKIs,
andwithprior experience inopen-label cabozantinib studies.24,26,31-33
Gastrointestinal perforations, fistula development, and hemorrhage
occurred in the cabozantinib arm of this study. These potentially
life-threatening AEs have previously been observed with VEGF path-
way inhibition35 and require caution, especiallywhen treatingpatients
who are at risk for such events. We did not observe clinically relevant
QTcF prolongation of more than 500 milliseconds, as was encoun-
tered in the vandetanib phase III trial.24
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Fig 3. Correlation between changes in calcitonin or carcinoembryonic antigen
(CEA) and changes in tumor size. Calcitonin and CEA are shown compared with
changes in the sum of tumor diameters from baseline to week 12; a roughly
linear relationship is observed between changes in these biomarkers and
changes in tumor target lesion size up through approximately 200% increase in
each tumor marker. (A) Percent change in calcitonin levels from baseline to week
12. Cabozantinib, n 131; placebo, n 54. Linear regression of data through two
standard deviations of calcitonin data (100    181.5). For all patients,
change in sum of tumor diameters  9.216  (0.1896  change in calcitonin);
r  0.56; P  .001. For cabozantinib arm only, change in sum of tumor
diameters  17.01  (0.1084  change in calcitonin); r  0.27; P  .0019. Six
points more than 181.5% change in calcitonin (change in sum of tumor diameters
ranging from 16.6% to 37.5%) are not included in the analysis. (B) Percent
change in CEA levels from baseline to week 12. Cabozantinib, n  159; placebo,
n  63. Linear regression of data through two standard deviations of CEA data
(100    243.5). For all patients, change in sum of tumor diameters 
13.95  (0.1727  change in CEA); r  0.56; P  .001. For cabozantinib arm
only, change in sum of tumor diameters  20.90  (0.0908  change in CEA);
r  0.23; P  .0042. Four points more than 243.5% change in CEA (change in
sum of tumor diameters ranging from 34.5% to 37.5%) are not included in the
analysis. IRC, independent radiology review committee.
Table 2. AEs Occurring in  10% of Cabozantinib-Treated Patients, by
Maximum Severity Reported
AE
Cabozantinib (n  214) Placebo (n  109)
All Grades Grade  3 All Grades Grade  3
No. % No. % No. % No. %
Diarrhea 135 63.1 34 15.9 36 33.0 2 1.8
Palmar-plantar
erythrodysesthesia 107 50.0 27 12.6 2 1.8 0
Decreased weight 102 47.7 10 4.7 11 10.1 0
Decreased appetite 98 45.8 10 4.7 17 15.6 1 0.9
Nausea 92 43.0 3 1.4 23 21.1 0
Fatigue 87 40.7 20 9.3 31 28.4 3 2.8
Dysgeusia 73 34.1 1 0.5 6 5.5 0
Hair color changes 72 33.6 1 0.5 1 0.9 0
Hypertension 70 32.7 18 8.4 5 4.6 1 0.9
Stomatitis 62 29.0 4 1.9 3 2.8 0
Constipation 57 26.6 0 6 5.5 0
Hemorrhage 54 25.2 7 3.3 17 15.6 1 0.9
Vomiting 52 24.3 5 2.3 2 1.8 1 0.9
Mucosal inflammation 50 23.4 7 3.3 4 3.7 0
Asthenia 45 21.0 12 5.6 16 14.7 2 1.8
Dysphonia 43 20.1 0 10 9.2 0
Rash 41 19.2 2 0.9 11 10.1 0
Dry skin 41 19.2 0 3 2.8 0
Headache 39 18.2 1 0.5 9 8.3 0
Oropharyngeal pain 38 17.8 1 0.5 5 4.6 0
Abdominal pain 36 16.8 6 2.8 7 6.4 1 0.9
Alopecia 35 16.4 0 2 1.8 0
Pain in extremity 33 15.4 3 1.4 12 11.0 1 0.9
Back pain 32 15.0 5 2.3 12 11.0 1 0.9
Dyspnea 29 13.6 5 2.3 19 17.4 11 10.1
Arthralgia 29 13.6 2 0.9 8 7.3 0
Dizziness 29 13.6 1 0.5 8 7.3 0
Oral pain 29 13.6 1 0.5 1 0.9 0
Dry mouth 28 13.1 0 9 8.3 0
Dysphagia 27 12.6 9 4.2 7 6.4 1 0.9
Cough 26 12.1 1 0.5 14 12.8 0
Muscle spasms 26 12.1 1 0.5 5 4.6 0
Dyspepsia 24 11.2 0 0 0
Insomnia 23 10.7 0 7 6.4 0
Erythema 23 10.7 2 0.9 2 1.8 0
Glossodynia 22 10.3 3 1.4 0 0
NOTE. Laboratory abnormalities are not included.
Abbreviation: AE, adverse event.
Hand-foot syndrome.
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Metabolic changes reported in the cabozantinib arm included
increased TSH and hypocalcemia. Increased TSH has been reported
during treatmentwith other TKIs, and is possibly a result of increased
type 3 deiodinase activity.36 Notably, most of the study patients had a
prior thyroidectomy and were receiving thyroid hormone and cal-
cium supplementation at baseline.
AEs were managed with supportive care and with dose reduc-
tions and holds allowing for patients to remain on treatment for
extended periods of time, which is similar to what has been observed
with other TKIs.24,31-33,37 However, the rate of holds and reductions
due to AEs was high, and evaluation of a lower starting dose of
cabozantinib versus 140 mg in patients with progressive, metastatic
MTC is planned.
Cabozantinib treatment substantially improves PFS and re-
sponse rates andhas amanageableAEprofile inpatientswithprogres-
sive metastatic MTC, including those previously treated with TKIs.
Cabozantinib has been approved by theUS Food andDrug Adminis-
tration for the treatment of patientswith progressive,metastaticMTC
and represents an important new therapeutic option for patients with
this rare malignancy.
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